NovioGendix is a molecular diagnostics company spun out from Radboud University Nijmegen Medical Centre (RUNMC), the Netherlands.

Over the next two years, MDxHealth and NovioGendix will use the grant to discover and validate tumor markers for the prediction of tumor progression into the muscle in developing invasive stage of bladder cancer.

Both the companies will use DNA methylation technologies, DNA sequencing and RNA-expression profiles on clinical samples collected from bladder cancer patients at the Urology Department of RUNMC.

MDxHealth CEO Jan Groen said the grant provides MDxHealth and NovioGendix with the necessary resources to investigate further the unique biological indicators and patterns seen in bladder cancer derived from patient samples from the existing collaboration of NovioGendix with RUNMC.

Eurotrans-Bio is a European Commission initiative to foster cross border R&D between companies and academia working in the biotech industry.